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Differential DNA Methylation in Umbilical Cord Blood of Infants Exposed 
to Low Levels of Arsenic in Utero
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Background: There is increasing epidemiologic evidence that arsenic exposure in utero, even at low 
levels found throughout much of the world, is associated with adverse reproductive outcomes and may 
contribute to long-term health effects. Animal models, in vitro studies, and human cancer data suggest 
that arsenic may induce epigenetic alterations, specifically by altering patterns of DNA methylation.
oBjectives: In this study we aimed to identify differences in DNA methylation in cord blood 
samples of infants with in utero, low-level arsenic exposure.
Methods: DNA methylation of cord-blood derived DNA from 134 infants involved in a prospec-
tive birth cohort in New Hampshire was profiled using the Illumina Infinium Methylation450K 
array. In utero arsenic exposure was estimated using maternal urine samples collected at 24–28 weeks 
gestation. We used a novel cell mixture deconvolution methodology for examining the association 
between inferred white blood cell mixtures in infant cord blood and in utero arsenic exposure; we also 
 examined the association between methylation at individual CpG loci and arsenic exposure levels.
results: We found an association between urinary inorganic arsenic concentration and the esti-
mated proportion of CD8+ T lymphocytes (1.18; 95% CI: 0.12, 2.23). Among the top 100 CpG 
loci with the lowest p-values based on their association with urinary arsenic levels, there was a sta-
tistically significant enrichment of these loci in CpG islands (p = 0.009). Of those in CpG islands 
(n = 44), most (75%) exhibited higher methylation levels in the highest exposed group compared 
with the lowest exposed group. Also, several CpG loci exhibited a linear dose-dependent relation-
ship between methylation and arsenic exposure.
conclusions: Our findings suggest that in utero exposure to low levels of arsenic may affect the 
epigenome. Long-term follow-up is planned to determine whether the observed changes are associ-
ated with health outcomes.
key words: arsenic, cord blood, DNA methylation, epigenetics, Illumina 450K, in utero arsenic 
exposure.
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Introduction
Arsenic, an established environmental toxi-
cant, has been linked to numerous adverse 
health outcomes, including cardiovascular dis-
ease (Chen et al. 2011; Gong and O’Bryant 
2012), cancer (Hopenhayn-Rich et al. 1998), 
and skin lesions (Yunus et al. 2011). There is 
also a growing concern regarding the effects 
of in utero exposure to arsenic on the devel-
oping fetus (Vahter 2008). Recent stud-
ies have reported that high-level exposure to 
arsenic in utero is associated with increased 
infant mortality, low birth weight, and birth 
defects (Rahman et al. 2009, 2010). Most 
previous studies of arsenic exposure and new-
born health outcomes, however, have focused 
primarily on populations in arsenic-endemic 
regions, outside the United States (Vahter 
2008). Whereas occupational exposure to 
arsenic and contaminated drinking water were 
once considered the primary means of arsenic 
exposure, dietary intake of arsenic, particularly 
from rice consumption, potentially may con-
tribute to the same extent as drinking water in 
exposing pregnant women to arsenic (Gilbert-
Diamond et al. 2011). This finding has raised 
concerns regarding the possible health conse-
quences associated with fetal exposure to what 
may be relatively common levels of arsenic. 
Yet there exists a gap in current knowledge 
as to whether findings from populations in 
arsenic endemic regions of the world can be 
used to infer the risks associated with low-level 
arsenic exposure, common to much of the 
United States.
Emerging data now suggest that arsenic 
may induce epigenetic alterations, specifi-
cally by altering patterns of DNA methylation 
(Reichard and Puga 2010; Ren et al. 2011). 
Differences in global DNA methylation asso-
ciated with exposure to arsenic have been 
reported based on animal (Davis et al. 2000; 
Zhao et al. 1997), in vitro (Mass and Wang 
1997), and human studies across various tissue 
types (i.e., umbilical cord blood and periph-
eral blood in adult subjects) (Intarasunanont 
et al. 2012; Wilhelm et al. 2010). The pat-
terns of DNA methylation alteration associ-
ated with arsenic exposure have been far 
from consistent, with several studies report-
ing reductions in global DNA methylation 
(Intarasunanont et al. 2012; Wilhelm et al. 
2010; Zhao et al. 1997) and others reporting 
evidence of global hypermethylation (Davis 
et al. 2000; Mass and Wang 1997). Factors 
including the type of markers used for assess-
ment of global methylation, the biological 
sample in which DNA methylation was mea-
sured, and modifiers such as nutritional folate 
levels (Pilsner et al. 2007) may explain the dif-
ferential findings. In the context of prenatal 
exposure to arsenic, two recently published 
studies of different Bangladesh cohorts have 
reported positive associations between LINE-1 
repeat element methylation in cord blood and 
arsenic exposure in utero (Kile et al. 2012; 
Pilsner et al. 2012), although no significant 
associations were observed in a cross-sectional 
study conducted in Thailand (Intarasunanont 
et al. 2012).
Beyond global methylation alterations, 
several recent epidemiologic studies have 
reported positive gene-specific associations 
between in utero exposure to arsenic and 
promoter methylation of CDKN2A (encod-
ing p16INK4A) (Kile et al. 2012) and TP53 
(Intarasunanont et al. 2012) measured in 
human umbilical cord peripheral blood lym-
phocytes (PBLs). However, the reported asso-
ciations of these two studies correspond to 
very modest differences in DNA methyla-
tion, even though these studies consisted of 
individuals residing in the areas of the world 
with the highest purported levels of arsenic 
exposure. These studies, as well as studies of 
adults, have measured DNA methylation in 
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unfractioned PBLs, which are relatively easy 
to collect and process. However, the primary 
limitation is that methylation signatures in 
PBLs represent the aggregate methylation 
profile of a complex cellular mixture. Thus, 
even small changes in percent methylation 
may indicate considerable differences in 
underlying cell populations, reflecting immu-
nomodulation. Arsenic exposure has been 
associated with immune suppression and 
impaired macrophage function in exposed 
populations (Banerjee et al. 2009; Selgrade 
2007). Hence, one possible mechanism for 
arsenic-induced diseases in exposed popu-
lations is altered immune function related 
to alterations of immune cell populations, 
which may be evident in blood-based pro-
files of DNA methylation. Dissecting out the 
contributions of different cell types and direct 
changes to the methylome on the observed 
associations between arsenic exposure and 
gene-specific DNA methylation patterns is 
critical for understanding the mechanisms of 
arsenic’s immunotoxic effects. To address this 
limitation, our group has begun to use DNA 
methylation signatures of known cell types as 
a surrogate for defining cell mixture propor-
tions (Houseman et al. 2012); by applying 
this methodology, we are able to interrogate 
not only arsenic’s effect on DNA methylation 
but also its effect on relative  leukocyte sub-
type proportions.
Despite the collective evidence support-
ing the role of arsenic exposure on the dys-
regulation of DNA methylation, little is known 
about potential effects of low levels of arsenic 
in utero—common to much of the world’s 
population—on DNA methylation. Moreover, 
the extent to which such patterns reflect immu-
nomodulation, indicated by shifts in leukocyte 
subpopulations, or represent changes in the 
underlying methylome, has not been previously 
examined. We aimed to address these ques-
tions by examining the association between 
low-level arsenic exposure at 24–28 weeks 
gestation, a period of exposure during which 
DNA methylation patterns are becoming 
set in hematopoetic stem cells (Rodak et al. 
2007), and patterns of  epigenome-wide DNA 
methylation in umbilical cord blood samples 
from 134 mother–infant pairs enrolled in a 
U.S.-based cohort study.
Methods
Study population. The study population 
consisted of the 134 initial participants of 
the ongoing New Hampshire Birth Cohort 
Study (NHBCS), which focuses on pregnant 
women from New Hampshire, whose pri-
mary household drinking-water source was a 
private well (Gilbert-Diamond et al. 2011). 
Eligibility criteria included English speaking, 
English literate, and mentally competent preg-
nant women 18–45 years of age. Subjects who 
changed their residence since their last men-
strual period or whose home water supply was 
from a source other than from a private well 
were excluded from the study. Demographic 
and lifestyle information was collected during 
routine prenatal visits, and for the infant from 
the newborn medical chart. This study was 
approved by the Committee for the Protection 
of Human Subjects at Dartmouth College. All 
study participants provided written informed 
consent prior to the study.
Arsenic exposure assessment. As previously 
described (Gilbert-Diamond et al. 2011), spot 
urine samples were collected at approximately 
24–28 weeks gestation into acid-washed con-
tainers that contained 30 μL of 10 mM diam-
monium diethyldithiocarbamate to stabilize 
arsenic species, and frozen at –80°C until 
analysis (within 24 hr of collection). Samples 
were analyzed for individual species of uri-
nary arsenic using a high-performance liquid 
chromatography inductively coupled plasma 
mass spectrometry (ICP-MS) system, and uri-
nary creatinine levels were assessed to control 
for urinary dilution. The arsenic speciation 
method is capable of quantitatively deter-
mining five arsenic species in urine: arsenite 
(AsIII), arsenate (AsV), dimethylarsinic acid 
(DMAV), monomethylarsonic acid (MMAV), 
and arsenobetaine. The separated arsenic spe-
cies were detected by ICP-MS using time-
resolved analysis at m/z 75. The detection 
limits ranged from 0.10 to 0.15 μg/L for the 
individual arsenic species. Values for samples 
with measurements below the limit of detec-
tion were taken to be the median between 
0 μg/L and the detection limit for that arsenic 
species. We calculated total urinary arsenic 
concentrations (U-As) by summing inorganic 
arsenic (iAs; AsIII and AsV) and the metabolic 
products MMAV and DMAV. Arsenobetaine 
was excluded from this calculation because it 
is thought to be nontoxic and to pass through 
the body without being metabolized. We used 
total U-As as a measure of in utero exposure 
to arsenic because urinary arsenic levels have 
been suggested to provide reliable indica-
tions of internal dose (Marchiset-Ferlay et al. 
2012), and arsenic is known to readily cross 
the placenta, leading to fetal serum concen-
trations similar to maternal levels (Concha 
et al. 1998). As a measure of methylation 
efficiency, we have also calculated the ratio 
of inorganic to total urinary arsenic [iAs/
(iAs + MMAV + DMAV)].
DNA methylation assessment and quality 
control. DNA was isolated from cord blood 
samples using DNeasy® blood & tissue kits 
(Qiagen, Valencia, CA) and bisulfite con-
verted using the EZ DNA Methylation kit 
(Zymo, Irvine, CA). Samples were random-
ized across several plates and subsequently 
subjected to epigenome-wide DNA methyla-
tion assessment using the Illumina Infinium 
HumanMethylation450 BeadChip (Illumina, 
San Diego, CA), which simultaneously pro-
files the methylation status for > 485,000 
CpG sites at single-nucleotide resolution. 
Microarrays were processed at the Biomedical 
Genomics Center at the University of 
Minnesota (Minneapolis, MN), following 
standard protocols. The methylation status for 
each individual CpG locus was calculated as 
the ratio of fluorescent signals (β = Max(M,0)/
[Max(M,0) + Max(U,0) + 100]), ranging from 
0 (no methylation) to 1 (complete methyla-
tion), using the average probe intensity for the 
methylated (M) and unmethylated (U) alleles. 
The data were assembled using BeadStudio 
methylation software (Illumina, San Diego, 
CA), without normalization per the manu-
facturer’s instructions. We used array control 
probes to assess the quality of our samples 
and evaluate potential problems such as poor 
bisulfite conversion or color-specific issues for 
each array (Marsit et al. 2009). All CpG loci 
on X and Y chromosomes and all loci within 
100bp of known single-nucleotide polymor-
phisms (SNPs) (determined using the annota-
tion for the Illumina HumanMethylation450 
array) were excluded from the analysis to 
avoid sex-specific methylation bias and biases 
related to genetic variability, respectively, leav-
ing 385,249 autosomal CpG loci for analy-
sis in 134 samples. Technical validation of 
the methylation array measurements was 
obtained using bisulfite pyrosequencing [for 




Principal components analysis and adjustment 
for plate effects. DNA methylation values were 
logit [i.e., log(β/1–β)] transformed as in previ-
ous studies (Du et al. 2010; Kuan et al. 2010). 
To de-convolve the most prevalent sources 
of variability in DNA methylation across the 
array, we performed a principal components 
analysis (PCA) on the resulting methylation 
data (Harper et al. 2013; Yang et al. 2010). 
PCA represents a feature extraction technique 
where the methylation data is orthogonally 
transformed, such that the first principal 
component has the largest possible variance 
(accounts for maximal amount of variability 
in the methylation data), and each succeeding 
component in turn has the next highest vari-
ance possible. The resulting top three principal 
components (those representing the maximum 
proportion of variability in methylation) were 
then examined in terms of their association 
with technical aspects concerning the array 
(i.e., plate/BeadChip) and patient demo-
graphic information using a series of linear 
regression models [see Supplemental Material, 
Figures S1–S2 and Table S1 (http://dx.doi.
org/10.1289/ehp.1205925)]. Because the 
Low-level in utero exposure to arsenic
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top three principal components were signifi-
cantly associated with plate (se Supplemental 
Material, Figure S2, Table S1), suggesting 
that plate was a major source of variability in 
methylation across the array, we adjusted for 
plate effects by applying the ComBat method 
(Johnson et al. 2007). Following a similar 
procedure, we then investigated the result-
ing plate-adjusted methylation data to ensure 
that variation in methylation across the array 
induced by plate effects had been success-
fully attenuated (see Supplemental Material, 
Figure S2, Table S2). We also investigated 
the top three principal components com-
puted from the plate-adjusted methylation 
data in terms of their association with arse-
nic exposure. Briefly, this was accomplished 
by fitting a series of linear regression models 
that modeled the principal component as the 
dependent variable and quartiles of U-As as 
an independent variable, which were adjusted 
for maternal age at delivery, infant sex, and 
urinary creatinine levels (Barr et al. 2005; 
Gamble and Liu 2005). Unless stated other-
wise, quartiles of U-As were used as measures 
of arsenic exposure because several studies 
have reported nonlinear relationships between 
arsenic exposure and patterns of DNA meth-
ylation at both gene-specific and genome-wide 
levels (Chanda et al. 2006; Majumdar et al. 
2010) and also to reduce any skewing of the 
data by outlying values.
Cell mixture deconvolution analysis. 
Using the plate-adjusted methylation data, 
we employed a novel statistical methodology 
(Houseman et al. 2012) for inferring changes 
in the distribution of leukocytes between 
quartiles of U-As using DNA methylation 
signatures, combined with a previously 
obtained external reference data set consist-
ing of methylation signatures from purified 
leukocyte samples (Houseman et al. 2012; 
Koestler et al. 2012). Further details regard-
ing the reference data set are provided else-
where (Houseman et al. 2012; Koestler et al. 
2012). A critical component of this approach 
is the set of DNA methylation signatures of 
the major leukocyte components of whole 
blood [i.e., B cells, natural killer (NK) cells, 
CD8+ T lymphocytes, CD4+ T lymphocytes, 
monocytes, and granulocytes]. The meth-
ods of Houseman et al. (2012) demonstrate 
that the distribution of white blood cells can 
be approximated from the DNA methyla-
tion measured in whole blood at the top 500 
leukocyte differentially methylated regions 
(L-DMRs); application of these methods 
allowed us to estimate the expected differ-
ence in cell type proportions between U-As 
quartiles 2, 3, and 4 and the referent quartile 
(quartile 1), as well as the expected change 
in cell type proportions based on a 1-μg/L 
increase in the concentration of the individual 
arsenic metabolites. 
In addition, the methods of Houseman 
et al. (2012) allowed us to quantify the propor-
tion of total variability in cord blood DNA 
methylation explained by estimated immune 
cell composition. Consistent with our other 
models, we adjusted for maternal age at deliv-
ery, infant sex, and urinary creatinine levels. 
We note several assumptions regarding the 
cell mixture deconvolution method. First, we 
assumed that the 500 L-DMRs—discerned 
using the methylation signature from purified 
leukocyte subtypes from healthy adults—are 
indeed biologically determinant of key differ-
ences in cell type across all ages, and therefore 
translate to cord-blood. We also assumed that 
the methylation status for the 500 L-DMRs 
used here is not systematically altered by expo-
sure to arsenic. We note other work (Koestler 
et al. 2013) that demonstrates the insensitivity 
of the methods to the deletion of some CpGs 
(e.g., those that show evidence of serving as 
age-DMRs)—that the accidental inclusion 
of some age-DMRs in the set are unlikely to 
influence results. Also, substantial biases due 
to arsenic exposure would require system-
atic alterations of methylation states at the 
500 L-DMRs in a manner consistent with the 
linear space spanned by the reference profiles, 
an event unlikely unless the alteration was itself 
implicated in perturbations of hematopoiesis.
Locus–locus analysis for detecting differen-
tially methylated CpG loci. We implemented a 
locus-by-locus analysis aimed toward identify-
ing differentially methylated CpG sites based 
on total urinary arsenic levels. Briefly, analysis 
of covariance models were fit to each CpG 
site separately, and modeled logit-transformed 
methylation as the response against quartiles 
of total urinary arsenic (quartile 1 treated as 
the referent group). Models for U-As were 
adjusted for maternal age at delivery, infant 
sex, and urinary creatinine levels. Although 
our examination was exploratory in nature, 
p-values were adjusted for multiple compari-
sons by computing the Benjamini–Hochberg 
adjusted p-values (Benjamini and Hochberg 
1995). CpG loci that exhibited a linear dose–
response relationship were identified by fit-
ting a series of linear regression models, which 
modeled U-As quartiles as a continuous 
covariate; U-As quartiles were assigned values 
of 1–4, for quartiles 1–4, respectively.
All analyses were carried out using the 
R statistical package, version 2.13 (Vienna, 
Austria; www.r-project.org/).
Results
Demographic and clinical information for 
the 134 mother–infant pairs is provided in 
Table 1. Home tap-water arsenic concentra-
tions ranged from close to the detection 
limit (0.03 μg/L) to nearly 100 μg/L, with 
22 women (18%) having home drinking water 
> 10 μg/L, the current U.S. Environmental 
Protection Agency (EPA) standard (U.S. 
EPA 2001). Total U-As, calculated by sum-
ming the concentrations of inorganic arsenic, 
MMAV, and DMAV, ranged from (0.45 μg/L) 
to nearly 300 μg/L, was highly right-skewed 
[see Supplemental Material, Figure S3 (http://
dx.doi.org/10.1289/ehp.1205925)], and had 
a median concentration of 4.1 μg/L [interquar-
tile range (IQR), 1.8–6.6], which is similar 
to the median estimated for the U.S. popula-
tion as a whole (Caldwell et al. 2009). A sin-
gle outlying sample with a urinary As value of 
nearly 300 μg/L was confirmed. Because of 
the skew of the data and this outlier, as well as 
the potential nonlinear relationship between 
arsenic exposure and DNA methylation, we 
examined total urinary arsenic in all analy-
ses as a categorical variable splitting the data 
in quartiles.
Supplemental Material, Table S3 (http://
dx.doi.org/10.1289/ehp.1205925) pres-
ents coefficient estimates and corresponding 
p-values for quartiles of total U-As and their 
association with shifts in estimated lympho-
cyte subsets. Coefficient estimates for each 
cell type reflect the estimated percent dif-
ference in the proportion of that cell type 
between U-As quartiles 2–4 relative to the 
lowest quartile (quartile 1). There were no 
statistically significant overall differences in 
the proportions of cell types among quartiles 
Table 1. Demographic, clinical, and phenotypic 
information for the study population. 
Characteristic Value
No. of mother–child pairs 134
Maternal age at delivery (years) 31 ± 4.6
Gestational age (weeks) 40 ± 1.3














Less than 11th grade 2 (1)
High school graduate or equivalent 11 (8)
Junior college graduate or some 
college or technical school
30 (22)
College graduate 48 (36)
Postgraduate schooling 21 (16)
Unknown 22 (16)
Maternal urinary As (μg/L) 4.1 (1.8–6.6)
iAs (μg/L)a 0.25 (0.13–0.47)
MMAV (μg/L) 0.31 (0.15–0.5)
DMAV (μg/L) 3.4 (1.6–5.7)
Tap-water arsenic (μg/L) 1.2 (0.2–6.2)
Values are presented as mean ± SD, n (%), or median 
(interquartile range). 
aFifty-six samples had measurements below the limit of 
detection for iAs.
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of total U-As. Table 2 provides the results of 
this model fit to continuous values of total 
urinary inorganic As and metabolites indi-
vidually where the coefficient estimates rep-
resent the estimated change in the proportion 
of a particular cell type based on a 1-μg/L 
increase in the levels of these metabolites. For 
iAs/(iAs + MMAV + DMAV), the coefficient 
estimates represent the expected difference in 
cell type proportions for a 1-unit increase in 
the proportion of inorganic As to total U-As. 
There was a statistically significant positive 
association between a 1-μg/L increase in inor-
ganic arsenic and the proportion of CD8+ 
T lymphocytes (1.18; 95% CI: 0.12, 2.23) 
(Table 2). CD8+ T lymphocytes also were 
associated with a 1-unit increase in the ratio 
of inorganic arsenic to total urinary arsenic 
(9.11; 95% CI: 0.44, 17.79), but were not 
significantly associated with other fractions 
(i.e., MMAV and DMAV; Table 2).
Overall, however, white blood cell dis-
tributions explained a relatively small pro-
portion of the variability in patterns of cord 
blood DNA methylation associated with 
in utero exposure to arsenic (3% for total 
U-As), so the remaining systematic source of 
variation was hypothesized to be alterations 
to the methylome itself in some or all of the 
cell populations examined. We first used PCA 
to reduce the dimensionality of the genome-
wide DNA methylation data and to inves-
tigate the extent to which low-level arsenic 
exposure in utero was associated with genome-
wide variability in cord blood DNA methyla-
tion in our population. The results of this 
analysis [see Supplemental Material, Table S4 
(http://dx.doi.org/10.1289/ehp.1205925)] 
revealed no statistically significant association 
between U-As quartiles and principal compo-
nents 1–3, which were estimated to account 
for 20%, 12%, and 9% of the variation in 
methylation across the array.
To identify individual CpG loci whose 
methylation status was associated with expo-
sure, we next examined differential locus-
specific patterns of DNA methylation based 
on total U-As levels. As shown in Figure 1A, 
which depicts –log10(p-values) (y-axis) for 
the association between U-As quartiles and 
the methylation of individual CpG loci (the 
dependent variable), 68,353 of 385,249 CpG 
loci (18%) were significantly associated with 
exposure (p < 0.05 for a difference over all 
quartiles of U-As), controlling for mater-
nal age at delivery, infant sex, and urinary 
 creatinine levels. However no association 
was statistically significant after adjusting for 
multiple comparisons. Among the 100 CpG 
loci with the smallest unadjusted p-values 
for the difference in methylation over all 
U-As quartiles [see Supplemental Material, 
Table S5 (http://dx.doi.org/10.1289/
ehp.1205925)], there was a statistically 
significantly greater than expected propor-
tion of loci located in CpG Islands (Fisher’s 
exact p = 0.009) (Figure 1B), and of those 
in CpG Islands (n = 44), most (75%) exhib-
ited higher methylation levels in the high-
est exposed group (quartile 4) compared 
with the lowest exposed group (quartile 1). 
Furthermore, a number of differentially 
methylated CpG loci displayed a linear dose–
response relationship across the quartiles of 
total U-As levels (see Supplemental Material, 
Table S6). Most notably, our analysis iden-
tified cg08884395 and cg27514608, associ-
ated with genes ESR1 (estrogen receptor 1) 
and PPARGC1A (peroxisome proliferator– 
activated receptor-γ coactivator 1-α), respec-
tively (Figure 2), which both exhibited a 
negative association between methylation and 
arsenic exposure (linear trend p = 0.0009 for 
both). Considering the differences in toxicity 
of inorganic arsenic, MMA and DMA (Le 
et al. 2000), exposure to different forms of 
arsenic over the range of U-As concentrations 
could potentially confound our results. To 
examine the robustness of our results based 
on exposure to different forms of arsenic, we 
Table 2. Estimated change in the proportions of leukocyte types (95% CI) by continuous specific urinary arsenic exposure measures. 
Lymphocytes Myeloid cells
CD8+ T CD4+ T NK cells B cells Monocytes Granulocytes
iAs (per μg/L) 1.18 (0.12, 2.23)* –1.24 (–3.15, 0.68) –0.11 (–1.83, 1.62) –0.78 (–1.91, 0.36) –0.37 (–1.31, 0.56) 1.38 (–2.30, 5.06)
MMAV (per μg/L) 0.93 (–0.30, 2.15) –0.24 (–2.62, 2.14) –0.48 (–2.59, 1.62) –0.68 (–1.88, 0.52) –0.20 (–1.33, 0.93) 1.15 (0.53, –3.02, 5.32)
DMAV (per μg/L) 0.42 (–0.80, 1.64) –0.10 (–2.40, 2.20) –0.37 (–2.14, 1.41) –0.22 (–1.46, 1.01) –0.27 (–1.16, 0.62) 0.40 (–3.57, 4.36)
iAs/(iAs + MMAV + DMAV) 9.11 (0.44, 17.79)* –11.82 (–27.66, 4.02) –2.16 (–14.58, 10.27) –6.05 (–16.4, 4.27) –1.81 (–8.20, 4.58) 16.91 (–14.12, 47.92)
All four models were controlled for maternal age at delivery, infant sex, and urinary creatinine. Results are based on fitting the cell mixture deconvolution method separately for each 
arsenic measure (i.e., iAs, MMAV, etc.). Values are coefficient estimates (95% CIs), where the coefficient estimates represent the estimated change in the proportion of a particular cell 
type based on a 1-μg/L increase in the levels of these metabolites. For iAs/(iAs + MMAV + DMAV), the coefficient estimates represent the expected difference in cell type proportions 
for a 1-unit increase in the proportion of inorganic As to total U-As.
*p ≤ 0.05.
Figure 1. Locus-by-locus examination of differentially methylated CpG sites based on U-As levels. (A) Manhattan plot for total U-As, where points represent the 
-log10 (p-value) testing the null hypothesis of no difference in methylation across quartiles of arsenic exposure, adjusted for maternal age at delivery, infant sex, 
and urinary creatinine levels. Red and blue lines indicate –log10(1 × 10–4) and –log10(0.05), respectively. (B) Location of the top 100 CpGs associated with U-As 
on the basis of p-value (top 100 probes) compared with all CpGs on the methylation array (all probes). N. shore and N. shelf refer to CpG island shore and shelf 
regions, respectively, that are upstream of a CpG island region. S. shore and S. shelf refer to CpG island shore and shelf regions, respectively, that are down-
stream of a CpG island region.
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refit models to the CpG sites that exhibited 
a dose–response relationship and individually 
adjusted for urinary concentrations of inor-
ganic arsenic, MMA, and DMA. These results 
(see Supplemental Material, Tables S7–S9) 
indicated that adjustment for urinary arsenic 
metabolites had very little effect on the associ-
ation between quartiles of U-As and the DNA 
methylation of the dose–response CpG sites, 
with all p-values for trend remaining < 0.05.
As validation of the methylation array, 
two CpG loci (cg27308738, n=29; and 
cg10528424, n=30) were subjected to bisul-
fite pyrosequencing, because these loci were 
among the most variable across the study sam-
ples in terms of their methylation levels. Our 
results indicated a very high degree of cor-
relation between the methylation array values 
and the percent methylation measurements 
obtained from pyrosequencing (Pearson’s 
correlation coefficient = 0.98 and 0.93 for 
cg27308738 and cg10528424, respectively) 
[see Supplemental Material, Figure S4 (http://
dx.doi.org/10.1289/ehp.1205925)].
Discussion
Patterns of DNA methylation are established 
during embryogenesis and play an important 
role in gene transcription, chromosomal sta-
bility, X-chromosome inactivation, and tis-
sue differentiation. Alteration of fetal DNA 
methylation is a potential mechanism linking 
in utero exposures to chronic diseases in adult-
hood (Kile et al. 2012). The predominantly 
rural U.S. study population is distinct from 
prior study populations, which were mainly 
based outside of the United States and were 
typically exposed to greater levels of arsenic 
than those of the study population examined 
here. However, nearly 20% of this pregnant 
population was exposed to household drinking 
water above the U.S. EPA standard. Not sur-
prisingly, most women with household drink-
ing water above the U.S. EPA standard were 
among those with the highest urinary arsenic 
levels (data not shown). This is in line with 
our previous report (Gilbert-Diamond et al. 
2011) that arsenic exposure from private well 
water contributes appreciably to exposure in 
this population. Our results, which indicated 
some evidence of differential patterns of DNA 
methyla tion across the quartiles of arsenic expo-
sure, support additional investigation into the 
biologic effects of this level of arsenic exposure 
and provide further evidence for the need of 
public health efforts to reduce these exposures.
Animal and in vitro studies have demon-
strated effects of arsenic at environmentally 
relevant levels (i.e., 10–100 μg/L) on early 
immune response (Kozul et al. 2009a, 2009b; 
Martin-Chouly et al. 2011; Mattingly et al. 
2009), providing a potential biological mecha-
nism for health complications experienced by 
prenatally exposed arsenic individuals later 
in life. Here we examined whether low-level 
arsenic exposure at 24–28 weeks gestation, 
a period during which fetal hematopoiesis is 
shifting from the liver to the bone marrow 
(Rodak et al. 2007), was associated with the 
shifts in immune cells. Our results revealed 
a statistically significant positive association 
between the estimated proportion of CD8+ 
T lymphocytes and both inorganic arsenic 
and the proportion of inorganic arsenic to 
total urinary arsenic. Although the methyla-
ted species of arsenic also exhibited a posi-
tive association with CD8+ T lymphocytes, 
unlike inorganic arsenic, the association 
between MMA and DMA and CD8+ T lym-
phocytes did not meet statistical significance 
(Table 2). Concentrations of individual 
metabolites reflect exposure to inorganic arse-
nic, direct consumption of methylated forms, 
and methyla tion efficiency (Kile et al. 2009). 
Our findings of a stronger association with 
inorganic arsenic may be attributable partly 
to the varying toxicity of arsenic’s metabo-
lites or epigenetic activity of arsenic’s metabo-
lites. Thus, our results indicate that increased 
levels of urinary inorganic arsenic (due to 
greater in utero exposure and/or potentially 
reduced metabolism of inorganic arsenic to 
the methylated species) are associated with 
increased proportions of cord-blood CD8+ 
T lymphocytes. These results are consis-
tent with recent work in which adult mice 
exposed to 100 μg/L of arsenic over 5 weeks 
showed increased percentage and total levels 
of CD8+ T  lymphocytes (Kozul et al. 2009a). 
In humans, though, a recent report that evalu-
ated the effects of prenatal arsenic exposure 
on thymus function at birth in a Bangledeshi 
cohort of 130 mother–infant pairs raised the 
possibility that there may be functional deficits 
in CD8+ cells associated with arsenic expo-
sure in utero (Ahmed et al. 2012). Although 
we recognize that our findings are prelimi-
nary, we know of no prior studies reporting 
on relationships between arsenic exposure and 
cord blood immune cell proportions defined 
using DNA methylation profiles as a surro-
gate measure of leukocyte proportion. The 
potential importance of these findings is 
underscored by mounting scientific evidence 
demonstrating that CD8+ T lymphocytes 
contribute to the initiation, progression, and 
regulation of several pathogenic autoimmune 
responses (Walter and Santamaria 2005), 
possibly providing a mechanism by which 
in utero exposure to arsenic during relevant 
etiologic periods of hematopoiesis results in 
an increased risk of autoimmune related illness 
later in life (Tseng 2004). It will be critical to 
examine prospectively whether the alterations 
we have observed are linked to immunological 
consequences later in childhood as well as to 
validate our findings in additional cohorts.
We further investigated the extent to 
which low-level arsenic exposure in utero was 
associated with genome-wide DNA methyla-
tion variability, assessed using PCA based on 
DNA methylation in cord blood. This analysis 
revealed no significant associations between 
the top three principal components and quar-
tiles of U-As, suggesting that arsenic exposure 
may not lead to overt, genome-wide pertur-
bations in DNA methylation to the extent 
that had been suggested by studies of “global 
methylation” markers. Instead, we found by 
examining associations between arsenic and 
each CpG loci individually that 18% of the 
CpG loci tested were differentially methylated 
among quartiles of U-As (p < 0.05). However 
none of these associations remained significant 
after adjustment for multiple comparisons. 
We observed that the top 100 CpGs associ-
ated with total urinary arsenic on the basis of 
unadjusted p-values were disproportionately 
located in CpG islands, and most of these 
CpG loci had higher methylation levels in 
the highest exposed group (quartile 4) com-
pared with the lowest exposed group (quar-
tile 1). Such findings are in line with existing 
reports, which assert that arsenic exposure is 
associated with hypermethylation of promoter 
region CpG islands (Chen et al. 2001) and the 
Figure 2. Crude plots of DNA methylation for cg08884395 (A) and cg27514608 (B) by quartiles of total U-As 
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well-established role of promoter CpG island 
methylation in epigenetic gene control and 
disease states (Ferreira et al. 2012; Lorenzen 
et al. 2012). Additionally, there were a num-
ber of CpG sites that exhibited a linear dose–
response relationship with respect to quartiles 
of U-As [see Supplemental Material, Table S6 
(http://dx.doi.org/10.1289/ehp.1205925)], 
and those relationships remained robust to 
individual adjustment for the levels of arse-
nic’s metabolites (see Supplemental Material, 
Tables S7–S9). Although these results require 
further validation, they suggest that even 
low-level in utero exposure to arsenic may 
bring about gene- or CpG-specific epigen-
etic changes, which themselves may contribute 
to altered gene expression and downstream 
cellular function.
In addition to purported effects of arse-
nic as a carcinogen and immunotoxicant, a 
growing body of literature is demonstrating 
endocrine disruption as an additional mode of 
toxicity (Naujokas et al. 2013). We noted in 
our analyses that increased  levels of total urinary 
arsenic were associated with decreased meth-
ylation of cg08884395 (linear trend p = 0.0009) 
[Figure 2A; see also Supplemental Table S6 
(http://dx.doi.org/10.1289/ehp.1205925)], 
located in CpG island shore region of ESR1, 
encoding estrogen receptor α. Importantly, 
methylation of this gene was observed in a 
CpG island shore region—regions up to 2 kb 
flanking CpG island—which may be the most 
enriched with functional CpG sites (Irizarry 
et al. 2009). In addition, although not statisti-
cally significant after adjustment for multiple 
comparisons, our analysis revealed a decrease 
in the methyla tion of cg27514608, for increas-
ing quartiles of U-As (linear trend p = 0.0009) 
[Figure 2B; see also Supplemental Table S6 
(http://dx.doi.org/10.1289/ehp.1205925)]. 
This locus is associated with the gene 
PPARGC1A, encoding PGC-1α, a coactivator 
of several nuclear receptors including peroxi-
some proliferator-activated receptors α and γ, 
thyroid hormone receptor, mineral corticoid 
receptor, and estrogen receptors (Sugawara 
et al. 2001). The result with ESR1 is consis-
tent with a report of decreased methylation 
and increased expression of ESR1 with in vitro 
arsenic exposure in a breast cancer model 
(Du et al. 2012), whereas the association with 
PPARGC1A is consistent with a report dem-
onstrating up-regulation of this gene in arsenic-
induced Bowen’s disease, a skin carcinoma (Lee 
et al. 2011). Given the role of hormone recep-
tors and their pathways in fetal development 
and throughout childhood, and the role that 
arsenic may be playing in altering these path-
ways, our data suggest that epigenetic modes of 
altered regulation of endocrine pathways may 
also be important for future study.
There are notable limitations to the 
present study. Our study cohort is largely 
Caucasian, which could limit generalizabil-
ity. However, our focus on common expo-
sure levels is unique compared with studies 
based in arsenic-endemic regions. Although 
our study did not directly assess concentra-
tions of arsenic on umbilical cord blood as a 
measure of fetal exposure to arsenic, arsenic 
is known to readily cross the placenta, lead-
ing to fetal serum concentrations similar to 
maternal levels (Concha et al. 1998; Hall et al. 
2007). Also, the external reference set used in 
our cell mixture analysis, which consisted of 
DNA methyla tion signatures from purified 
white blood cells, was isolated from differ-
ent, anonymous, adult, nondiseased individ-
uals’ whole blood (Koestler et al. 2012). As 
differences in DNA methylation have been 
demonstrated in individuals of varying ages 
(Winnefeld and Lyko 2012), the white blood 
cell–specific methylation signatures may not 
accurately reflect cell-specific patterns of DNA 
methylation evident in cord blood, which 
consists primarily of infant blood. Further, 
our cell mixture analysis used signatures of 
DNA methylation as a surrogate for cell mix-
ture composition, whereas a complete assess-
ment of the immune profile would require 
flow cytometric measurements. Although 
the results from our locus-by-locus analysis 
showed some evidence of altered methylation 
with arsenic exposure, these results did not 
withstand multiple comparison corrections. 
Thus, these results need to be replicated in 
additional studies. Along the same lines, we 
do not have the power to consider differential 
effects by sex or other potential modifiers, but 
larger studies should consider such effects.
Conclusions
Our novel exploratory examination suggests 
that low-level arsenic exposure in utero may 
influence the infant epigenome. Particularly, 
our findings highlight the possibility that 
exposure to arsenic—even at levels common 
to much of the world’s population—during 
relevant etiologic periods of fetal development 
may induce shifts in underlying cell popula-
tions, as well as gene-specific alterations in 
DNA methylation. Long-term follow-up is 
planned to determine whether the observed 
changes are associated with short- and long-
term health outcomes.
RefeRences
Ahmed S, Ahsan KB, Kippler M, Mily A, Wagatsuma Y, 
Hoque AM, et al. 2012. In utero arsenic exposure is asso-
ciated with impaired thymic function in newborns possibly 
via oxidative stress and apoptosis. Toxicol Sci 129(2):305–
314; doi:10.1093/toxsci/kfs202.
Banerjee N, Banerjee S, Sen R, Bandyopadhyay A, Sarma N, 
Majumder P, et al. 2009. Chronic arsenic exposure impairs 
macrophage functions in the exposed individuals. J Clin 
Immunol 29:582–594.
Barr DB, Wilder LC, Caudill SP, Gonzalez AJ, Needham LL, 
Pirkle JL. 2005. Urinary creatinine concentrations in 
the U.S. population: implications for urinary biologic 
monitoring measurements. Environ Health Perspect 
113:192–200.
Benjamini Y, Hochberg Y. 1995. Controlling the false discovery 
rate–a practical and powerful approach to multiple test-
ing. J R Stat Soc B Met 57(1):289–300.
Caldwell KL, Jones RL, Verdon CP, Jarrett JM, Caudill SP, 
Osterloh JD. 2009. Levels of urinary total and speci-
ated arsenic in the US population: National Health and 
Nutrition Examination Survey 2003–2004. J Expo Sci 
Environ Epidemiol 19:59–68.
Chanda S, Dasgupta UB, Guhamazumder D, Gupta M, 
Chaudhuri U, Lahiri S, et al. 2006. DNA hypermethylation of 
promoter of gene p53 and p16 in arsenic-exposed people 
with and without malignancy. Toxicol Sci 89:431–437.
Chen H, Liu J, Merrick BA, Waalkes MP. 2001. Genetic events 
associated with arsenic-induced malignant transforma-
tion: applications of cDNA microarray technology. Mol 
Carcinog 30:79–87.
Chen Y, Graziano JH, Parvez F, Liu M, Slavkovich V, Kalra T, et al. 
2011. Arsenic exposure from drinking water and mortality 
from cardiovascular disease in bangladesh: prospective 
cohort study. BMJ 342:d2431; doi:10.1136/bmj.d2431 [Online 
5 May 2011].
Concha G, Vogler G, Lezcano D, Nermell B, Vahter M. 1998. 
Exposure to inorganic arsenic metabolites during early 
human development. Toxicol Sci 44:185–190.
Davis CD, Uthus EO, Finley JW. 2000. Dietary selenium and 
arsenic affect DNA methylation in vitro in Caco-2 cells and 
in vivo in rat liver and colon. J Nutr 130:2903–2909.
Du J, Zhou N, Liu H, Jiang F, Wang Y, Hu C, et al. 2012. Arsenic 
induces functional re-expression of estrogen receptor 
alpha by demethylation of DNA in estrogen receptor-
negative human breast cancer. PLoS One 7:e35957; 
doi:10.1371/journal.pone.0035957 [Online 27 April 2012].
Du P, Zhang X, Huang CC, Jafari N, Kibbe WA, Hou L, et al. 
2010. Comparison of beta-value and M-value methods 
for quantifying methylation levels by microarray analysis. 
BMC Bioinformatics 11:587; doi:10.1186/1471-2105-11-587 
[Online 30 November 2010].
Ferreira HJ, Heyn H, Moutinho C, Esteller M. 2012. CpG island 
hypermethylation-associated silencing of small nucleolar 
RNAs in human cancer. RNA Biol 9:881–890; doi:10.4161/
rna.19353 [Online 23 May 2012].
Gamble MV, Liu X. 2005. Urinary creatinine and arsenic metab-
olism [Letter]. Environ Health Perspect 113:A442. 
Gilbert-Diamond D, Cottingham KL, Gruber JF, Punshon T, 
Sayarath V, Gandolfi AJ, et al. 2011. Rice consumption 
contributes to arsenic exposure in US women. Proc Natl 
Acad Sci USA 108:20656–20660.
Gong G, O’Bryant SE. 2012. Low-level arsenic exposure, 
AS3MT gene polymorphism and cardiovascular diseases 
in rural texas counties. Environ Res 113:52–57.
Hall M, Gamble M, Slavkovich V, Liu X, Levy D, Cheng Z, et al. 
2007. Determinants of arsenic metabolism: blood arsenic 
metabolites, plasma folate, cobalamin, and homocysteine 
concentrations in maternal–newborn pairs. Environ Health 
Perspect 115:1503–1509.
Harper KN, Peters BA, Gamble MV. 2013. Batch effects 
and pathway analysis: two potential perils in can-
cer studies involving DNA methylation array analysis. 
Cancer Epidemiol Biomarkers Prev 22(6):1052–1060; 
doi:10.1158/1055-9965.
Hopenhayn-Rich C, Biggs ML, Smith AH. 1998. Lung and kidney 
cancer mortality associated with arsenic in drinking water 
in cordoba, argentina. Int J Epidemiol 27:561–569.
Houseman EA, Accomando WP, Koestler DC, Christensen BC, 
Marsit CJ, Nelson HH, et al. 2012. DNA methylation arrays 
as surrogate measures of cell mixture distribution. BMC 
Bioinformatics 13:86; doi:10.1186/1471-2105-13-86 [Online 
8 May 2012].
Intarasunanont P, Navasumrit P, Woraprasit S, Chaisatra K, 
Suk WA, Mahidol C, et al. 2012. Effects of arsenic expo-
sure on DNA methylation in cord blood samples from 
newborn babies and in a human lymphoblast cell line. 
Environ Health 11:31; doi:10.1186/1476-069X-11-31 [Online 
2 May 2012].
Irizarry RA, Ladd-Acosta C, Wen B, Wu Z, Montano C, 
Onyango P, et al. 2009. The human colon cancer methy-
lome shows similar hypo- and hypermethylation at con-
served tissue-specific CpG island shores. Nat Genet 
41:178–186.
Johnson WE, Li C, Rabinovic A. 2007. Adjusting batch effects in 
microarray expression data using empirical Bayes meth-
ods. Biostatistics 8:118–127.
Low-level in utero exposure to arsenic
Environmental Health Perspectives • volume 121 | number 8 | August 2013 977
Kile ML, Baccarelli A, Hoffman E, Tarantini L, Quamruzzaman Q, 
Rahman M, et al. 2012. Prenatal arsenic exposure and DNA 
methylation in maternal and umbilical cord blood leuko-
cytes. Environ Health Perspect 120:1061–1066.
Kile ML, Hoffman E, Hsueh YM, Afroz S, Quamruzzaman Q, 
Rahman M, et al. 2009. Variability in biomarkers of arsenic 
exposure and metabolism in adults over time. Environ 
Health Perspect 117:455–460.
Koestler DC, Christensen B, Karagas MR, Marsit CJ, 
Langevin SM, Kelsey KT, et al. 2013. Blood-based profiles 
of DNA methylation predict the underlying distribution of 
cell types: a validation analysis. Epigenetics. Available: 
http://www.landesbioscience.com/journals/epigenetics/
article/25430/ [Online 25 June 2013].
Koestler DC, Marsit CJ, Christensen BC, Accomando WP, 
Langevin SM, Houseman EA, et al. 2012. Peripheral blood 
immune cell methylation profiles are associated with non-
hematopoietic cancers. Cancer Epidemiol Biomarkers 
Prev 21(8):1293–1302; doi:10.1158/1055-9965.EPI-12-0361.
Kozul CD, Ely KH, Enelow RI, Hamilton JW. 2009a. Low-dose 
arsenic compromises the immune response to influenza A 
infection in vivo. Environ Health Perspect 117:1441–1447.
Kozul CD, Hampton TH, Davey JC, Gosse JA, Nomikos AP, 
Eisenhauer PL, et al. 2009b. Chronic exposure to arsenic 
in the drinking water alters the expression of immune 
response genes in mouse lung. Environ Health Perspect 
117:1108–1115.
Kuan PF, Wang S, Zhou X, Chu H. 2010. A statistical frame-
work for Illumina DNA methylation arrays. Bioinformatics 
26:2849–2855.
Le XC, Ma M, Cullen WR, Aposhian HV, Lu X, Zheng B. 2000. 
Determination of monomethylarsonous acid, a key arsenic 
methylation intermediate, in human urine. Environ Health 
Perspect 108:1015–1018.
Lee CH, Wu SB, Hong CH, Liao WT, Wu CY, Chen GS, et al. 
2011. Aberrant cell proliferation by enhanced mitochon-
drial biogenesis via mtTFA in arsenical skin cancers. Am J 
Pathol 178:2066–2076.
Lorenzen JM, Martino F, Thum T. 2012. Epigenetic modifica-
tions in cardiovascular disease. Basic Res Cardiol 107:245; 
doi:10.1007/s00395-012-0245-9.
Majumdar S, Chanda S, Ganguli B, Mazumder DN, Lahiri S, 
Dasgupta UB. 2010. Arsenic exposure induces genomic 
hypermethylation. Environ Toxicol 25:315–318.
Marchiset-Ferlay N, Savanovitch C, Sauvant-Rochat MP. 2012. 
What is the best biomarker to assess arsenic exposure via 
drinking water? Environ Int 39:150–171.
Marsit CJ, Christensen BC, Houseman EA, Karagas MR, 
Wrensch MR, Yeh RF, et  al. 2009. Epigenetic profil-
ing reveals etiologically distinct patterns of DNA meth-
ylation in head and neck squamous cell carcinoma. 
Carcinogenesis 30:416–422.
Martin-Chouly C, Morzadec C, Bonvalet M, Galibert MD, 
Fardel O, Vernhet L. 2011. Inorganic arsenic alters expres-
sion of immune and stress response genes in activated 
primary human T lymphocytes. Mol Immunol 48:956–965.
Mass MJ, Wang L. 1997. Arsenic alters cytosine methylation 
patterns of the promoter of the tumor suppressor gene p53 
in human lung cells: a model for a mechanism of carcino-
genesis. Mutat Res 386:263–277.
Mattingly CJ, Hampton TH, Brothers KM, Griffin NE, 
Planchart A. 2009. Perturbation of defense pathways by 
low-dose arsenic exposure in zebrafish embryos. Environ 
Health Perspect 117:981–987.
Naujokas MF, Anderson B, Ahsan H, Aposhian HV, Graziano JH, 
Thompson C, et al. 2013. The broad scope of health effects 
from chronic arsenic exposure: update on a worldwide 
public health problem. Environ Health Perspect 121:295–302.
Pilsner JR, Hall MN, Liu X, Ilievski V, Slavkovich V, Levy D, et al. 
2012. Influence of prenatal arsenic exposure and newborn 
sex on global methylation of cord blood DNA. PLoS One 
7:e37147; doi:10.1371/journal.pone.0037147 [Online 25 May 
2012].
Pilsner JR, Liu X, Ahsan H, Ilievski V, Slavkovich V, Levy D, 
et al. 2007. Genomic methylation of peripheral blood leuko-
cyte DNA: Influences of arsenic and folate in Bangladeshi 
adults. Am J Clin Nutr 86:1179–1186.
Rahman A, Persson LA, Nermell B, El Arifeen S, Ekstrom EC, 
Smith  AH, et  al. 2010. Arsenic exposure and risk of 
spontaneous abortion, stillbirth, and infant mortality. 
Epidemiology 21:797–804.
Rahman A, Vahter M, Smith AH, Nermell B, Yunus M, 
El Arifeen S, et al. 2009. Arsenic exposure during preg-
nancy and size at birth: a prospective cohort study in 
Bangladesh. Am J Epidemiol 169:304–312.
Reichard JF, Puga A. 2010. Effects of arsenic exposure on DNA 
methylation and epigenetic gene regulation. Epigenomics 
2:87–104.
Ren X, McHale CM, Skibola CF, Smith AH, Smith MT, Zhang L. 
2011. An emerging role for epigenetic dysregulation 
in arsenic toxicity and carcinogenesis. Environ Health 
Perspect 119:11–19.
Rodak BF, Fritsma GA, Doig K. 2007. Hematology: Clinical 
Principles and Applications. 3rd ed. Philadelphia:W.B. 
Saunders.
Selgrade MK. 2007. Immunotoxicity: the risk is real. Toxicol Sci 
100:328–332.
Sugawara A, Takeuchi K, Uruno A, Ikeda Y, Arima S, Kudo M, 
et al. 2001. Transcriptional suppression of type 1 angioten-
sin II receptor gene expression by peroxisome prolifera-
tor-activated receptor-γ in vascular smooth muscle cells. 
Endocrinology 142:3125–3134.
Tseng CH. 2004. The potential biological mechanisms of 
 arsenic-induced diabetes mellitus. Toxicol Appl Pharmacol 
197:67–83.
U.S. EPA (U.S. Environmental Protection Agency). 2001. 
National primary drinking water regulations; arsenic and 
clarifications to compliance and new source contami-
nants monitoring. Fed Reg 66(114):6976–7066.
Vahter M. 2008. Health effects of early life exposure to arsenic. 
Basic Clin Pharmacol Toxicol 102:204–211.
Walter U, Santamaria P. 2005. CD8+ T cells in autoimmunity. 
Curr Opin Immunol 17:624–631.
Wilhelm CS, Kelsey KT, Butler R, Plaza S, Gagne L, Zens MS, 
et al. 2010. Implications of LINE 1 methylation for bladder 
cancer risk in women. Clin Cancer Res 16:1682–1689.
Winnefeld M, Lyko F. 2012. The aging epigenome: DNA meth-
ylation from the cradle to the grave. Genome Biol 13:165; 
doi:10.1186/gb4033.
Yang HH, Hu N, Wang C, Ding T, Dunn BK, Goldstein AM, et al. 
2010. Influence of genetic background and tissue types 
on global DNA methylation patterns. PLoS One 5:e9355; 
doi:10.1371/journal.pone.0009355.
Yunus M, Sohel N, Hore SK, Rahman M. 2011. Arsenic expo-
sure and adverse health effects: a review of recent 
findings from arsenic and health studies in Matlab, 
Bangladesh. Kaohsiung J Med Sci 27:371–376.
Zhao CQ, Young MR, Diwan BA, Coogan TP, Waalkes MP. 1997. 
Association of arsenic-induced malignant transformation 
with DNA hypomethylation and aberrant gene expression. 
Proc Natl Acad Sci USA 94:10907–10912.
